In a word, LBP activates the Nrf2 signaling pathway to resist lead-induced kidney injury, which is at least related to the downregulation of keap1 by LBP, and the activation Nrf2 effect of the medium dose is the best. The gene discussed is NFE2L2; the disease is kidney injury.